Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological and neuropsychiatric disorders. The company’s core mission is to address unmet medical needs in conditions such as depression, anxiety, and cognitive impairment by harnessing its proprietary neuro-modulatory platform. Neuphoria’s approach integrates advanced molecular screening with insights into synaptic function, aiming to identify small-molecule and peptide candidates that restore or enhance neural circuitry.
Central to Neuphoria’s strategy is its discovery engine, which leverages high-throughput phenotypic assays and computational biology to uncover novel compounds that interact with targets implicated in brain diseases. Its lead asset, NEU-101, is currently in Phase 1 clinical evaluation for treatment-resistant major depressive disorder. In parallel, preclinical programs are advancing candidates aimed at neuroinflammation and synaptic repair, positioning the company to build a diversified pipeline across multiple therapeutic areas.
Founded in 2021 and headquartered in South San Francisco, Neuphoria operates research facilities in both the United States and Europe. The company collaborates with academic centers and contract research organizations to accelerate preclinical development and optimize translational models. Strategic partnerships support its efforts to scale manufacturing and prepare for future late-stage trials, while a dedicated regulatory affairs team works to align clinical plans with global health authority guidelines.
Neuphoria’s leadership team combines expertise from established biotech and academic backgrounds. Chief Executive Officer Dr. Nathaniel Johnson brings over 20 years of drug discovery experience, having previously led neuroscience programs at leading pharmaceutical firms. The executive team is complemented by Chief Scientific Officer Dr. Elena Martinez, whose research in synaptic biology underpins the company’s discovery platform, and Chief Medical Officer Dr. Karen Liu, a neurologist with extensive clinical trial oversight. Together, they guide Neuphoria’s pursuit of transformative therapies for patients with challenging neurological conditions.
